Literature DB >> 12793970

Screening for hypercoagulable syndromes following stroke.

Cheryl Bushnell1, Larry B Goldstein.   

Abstract

Patients with ischemic stroke of unclear etiology are often screened for hypercoagulable syndromes or thrombophilias. These have been recognized to cause venous thrombosis, and include hereditary deficiencies of coagulation factors, genetic mutations, or acquired disorders. However, the majority of coagulation disorders are only rarely associated with ischemic stroke. The tests most commonly used to screen for thrombophilias comprise a complex array of assays that may be unreliable in various settings, including acute thrombosis, inflammation, and uses of medications such as anticoagulants. The diagnostic yield of thrombophilia tests in unselected stroke patients is very low, but may improve with careful selection of younger patients who have an otherwise undetermined cause of stroke or a history of venous thrombosis or multiple miscarriages. Various strategies have been developed that can guide the selection of patients (based on specific characteristics) and tests in the evaluation of thrombophilias. Although the diagnosis of thrombophilia aids in the potential explanation of stroke etiology, the best regimen for secondary prevention treatment for the majority of thrombophilias is still unknown.

Entities:  

Mesh:

Year:  2003        PMID: 12793970     DOI: 10.1007/s11883-003-0052-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  49 in total

1.  Infarcts of undetermined cause: the NINCDS Stroke Data Bank.

Authors:  R L Sacco; J H Ellenberg; J P Mohr; T K Tatemichi; D B Hier; T R Price; P A Wolf
Journal:  Ann Neurol       Date:  1989-04       Impact factor: 10.422

2.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

3.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

Review 4.  Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.

Authors:  J W Eikelboom; E Lonn; J Genest; G Hankey; S Yusuf
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

5.  Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment.

Authors:  O Salomon; D M Steinberg; A Zivelin; S Gitel; R Dardik; N Rosenberg; S Berliner; A Inbal; A Many; A Lubetsky; D Varon; U Martinowitz; U Seligsohn
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

6.  Physician knowledge and practices in the evaluation of coagulopathies in stroke patients.

Authors:  Cheryl D Bushnell; Larry B Goldstein
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

7.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

8.  Factor V Leiden mutation in cerebral venous thrombosis.

Authors:  M Zuber; P Toulon; L Marnet; J L Mas
Journal:  Stroke       Date:  1996-10       Impact factor: 7.914

9.  Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.

Authors:  J G Ray
Journal:  Arch Intern Med       Date:  1998-10-26

10.  Lipoprotein(a) and ischemic cerebrovascular disease in young adults.

Authors:  M Nagayama; Y Shinohara; T Nagayama
Journal:  Stroke       Date:  1994-01       Impact factor: 7.914

View more
  1 in total

1.  Cost and utility in the diagnostic evaluation of stroke.

Authors:  James F Burke
Journal:  Continuum (Minneap Minn)       Date:  2014-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.